Marx N, Federici M, Schtt K, Mller-Wieland D, Ajjan RA, Antunes MJ, et al
It has been shown to decrease glucagon secretion, increase glucose uptake and glycogen synthesis in the peripheral tissues, delay gastric emptying, and increase satiety.4 GLP-1 was first discovered in 1987 by Bernhard Kreymann and Stephen Robert Bloom, who were affiliated with the Royal Postgraduate Medical School Department of Medicine at Hammersmith Hospital in London, England.5 They established the insulinotropic actions of GLP-1 in humans and found that they were more effective than the glucose-dependent insulinotropic polypeptide (GIP) in stimulating insulin and reducing peak plasma glucose concentrations.4,6 In 2005, the FDA approved the first subcutaneous GLP-1 receptor agonist, exenatide (Byetta
Overview related to growth hormone signaling: BPC-157 has been reported to increase the expression of growth hormone receptors in tendon fibroblasts [3]
Common gastrointestinal side-effects of GLP-1 drugs can include nausea, vomiting and diarrhea: again leading to fluid loss and dehydration
Semaglutide is the active ingredient sold under the brand name Ozempic, which is used primarily to control blood sugar in people with diabetes
